LANCE KORTESOJA: Open Payments
NPI 1114497930 · OKEMOS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$607 in 32 payments from 12 companies in 2025. Trend: 2023 $358 · 2024 $622 · 2025 $607
Food & beverage: $607
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $115 |
| Abbott Laboratories | 6 | $104 |
| PFIZER INC. | 4 | $79 |
| Otsuka America Pharmaceutical, Inc. | 3 | $68 |
| ABBVIE INC. | 4 | $60 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $45 |
| GlaxoSmithKline, LLC. | 2 | $31 |
| Gilead Sciences, Inc. | 1 | $29 |
| Dexcom, Inc. | 1 | $23 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $20 |
Products named: FREESTYLE LIBRE 3, REXULTI, Wegovy, VRAYLAR, ELIQUIS, NURTEC ODT, SHINGRIX, Ozempic.
Industry payments across MI — which companies pay providers there.
